1. Home
  2. ORMP vs AGEN Comparison

ORMP vs AGEN Comparison

Compare ORMP & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Oramed Pharmaceuticals Inc.

ORMP

Oramed Pharmaceuticals Inc.

HOLD

Current Price

$4.03

Market Cap

165.3M

Sector

Health Care

ML Signal

HOLD

Logo Agenus Inc.

AGEN

Agenus Inc.

HOLD

Current Price

$5.07

Market Cap

147.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ORMP
AGEN
Founded
2002
1994
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
165.3M
147.4M
IPO Year
2010
1999

Fundamental Metrics

Financial Performance
Metric
ORMP
AGEN
Price
$4.03
$5.07
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$14.50
AVG Volume (30 Days)
516.0K
8.0M
Earning Date
05-14-2026
05-12-2026
Dividend Yield
6.51%
N/A
EPS Growth
412.50
100.00
EPS
0.91
1.02
Revenue
$2,000,000.00
$42,877,086.00
Revenue This Year
N/A
$107.63
Revenue Next Year
N/A
N/A
P/E Ratio
$4.39
$4.98
Revenue Growth
49.25
89.95
52 Week Low
$1.98
$2.71
52 Week High
$5.19
$8.70

Technical Indicators

Market Signals
Indicator
ORMP
AGEN
Relative Strength Index (RSI) 44.27 66.55
Support Level $3.69 $3.09
Resistance Level $4.22 N/A
Average True Range (ATR) 0.34 0.57
MACD -0.07 0.24
Stochastic Oscillator 7.45 38.12

Price Performance

Historical Comparison
ORMP
AGEN

About ORMP Oramed Pharmaceuticals Inc.

Oramed Pharmaceuticals Inc is a pharmaceutical company that is engaged in the research and development of pharmaceutical solutions with a technology platform that allows for the oral delivery of therapeutic proteins. The company has developed an oral dosage form intended to withstand the harsh environment of the gastrointestinal tract and effectively deliver active insulin or other proteins. Its product pipeline includes ORMD-0801 for Diabetes, ORMD-0801 for NASH, and ORMD 0901.

About AGEN Agenus Inc.

Agenus Inc is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and infectious diseases. Its primary business is immuno-oncology (I-O), where it advances antibody-based programs designed to activate innate and adaptive immunity, overcome tumor immune evasion, and expand the number of patients who may benefit from immunotherapy. The Company's clinical program includes botensilimab (BOT or AGEN1181), both as a monotherapy and in combination with balstilimab (BAL), alongside a portfolio of other clinical-stage immuno-oncology assets that may be used independently or in combination therapies. The Company operates in the United States, which contributes the majority of its revenue, as well as in other international markets.

Share on Social Networks: